IPF Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation Phase I Clinical Study to Assess the Safety, Pharmacokinetics, and Immunogenicity of HLX6018 in Healthy Subjects
Verified date | June 2024 |
Source | Shanghai Henlius Biotech |
Contact | Yanhua Ding |
dingyanhua2003[@]126.com | |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to investigate the safety, PK, and immunogenicity of a single intravenous administration of HLX6018 in healthy subjects, based on the preliminary efficacy and safety established through in vitro and in vivo experiments. This is a randomized, double-blind, placebo-controlled study with single dose escalation design to assess the safety, PK, and immunogenicity of HLX6018 in healthy subjects. It is planned to enroll 8-10 subjects in each of seven dose groups (0.25 mg/kg, 1.0 mg/kg, 4.0 mg/kg, 12 mg/kg, 25 mg/kg, 50 mg/kg, and 70 mg/kg). This is the first-in-human study of the investigational product.
Status | Recruiting |
Enrollment | 66 |
Est. completion date | December 30, 2026 |
Est. primary completion date | December 30, 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 55 Years |
Eligibility | Inclusion Criteria: 1. Fully informed about the nature, significance, potential inconveniences, and associated risks of the study prior to enrollment. Comprehend the study's procedures and methodology, agree to follow the clinical study protocol, and give voluntary written informed consent; 2. 18-55 years old, including the boundary value, male or female; 3. Body weight: 45-85 kg for females and 50-85 kg for males, including the boundary value; body mass index (BMI): 18.0-28.0 kg/m2 , including the boundary value, (BMI = body weight (kg)/body height2 (m2)); 4. Subjects, including males, must have no childbearing plan and take effective contraceptive measures from the time of informed consent to 6 months after the administration of the study drug. 5. Physical examinations and vital signs should be normal or abnormal without clinical significance. Exclusion Criteria: 1. Any clinically significant laboratory test abnormalities or, within 12 months before screening, any other clinically significant clinical findings indicative of diseases, including but not limited to gastrointestinal, renal, hepatic, neurological, hematological, endocrine, oncological, pulmonary, immunological, psychiatric, or cardiovascular conditions; 2. Donation/loss of = 450 mL of blood or receipt of blood transfusion or use of blood products within 3 months prior to screening, or planning to donate blood during the study or within 1 month after the end of the study; 3. Patients with severe trauma or major surgery within 3 months before screening, or planning to undergo surgery during the study; 4. Patients who smoke more than 5 cigarettes per day in the 3 months before screening; 5. History of drug abuse or addiction or alcohol abuse (14 units of alcohol per week: 1 unit = 285 mL of beer, or 25 mL of spirits, or 100 mL of wine); |
Country | Name | City | State |
---|---|---|---|
China | First Hospital of Jilin University | Changchun | Jilin |
Lead Sponsor | Collaborator |
---|---|
Shanghai Henlius Biotech |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The number of subjects experiencing adverse events (AEs) and serious adverse events (SAEs) | Safety evaluation | 0 to Day 99 | |
Secondary | AUC0-inf | Area under the serum concentration-time curve | 0 to Day 99 | |
Secondary | Cmax | Peak concentration | 0 to Day 99 | |
Secondary | Tmax | Time to reach peak concentration | 0 to Day 99 | |
Secondary | T1/2 | Terminal elimination half-life | 0 to Day 99 | |
Secondary | CL | Clearance | 0 to Day 99 | |
Secondary | ?z | Terminal elimination rate constant | 0 to Day 99 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05570058 -
Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis
|
Phase 2 | |
Recruiting |
NCT02807025 -
Nasal, Tracheal and Bronchial Mucosal Lining Fluid(MLF) Sampling From Patients With Respiratory Diseases
|
N/A | |
Recruiting |
NCT05895565 -
A Multiple Ascending Doses (MAD) Study of PMG1015 in Idiopathic Pulmonary Fibrosis Subjects
|
Phase 1 | |
Completed |
NCT03211507 -
Idiopathic Pulmonary Fibrosis Job Exposures Study
|
||
Completed |
NCT02503657 -
Safety and Tolerability Study in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
|
Phase 2 | |
Recruiting |
NCT03873298 -
Inhaled NO in IPF and COPD During 6 Minute Walk Test
|
Phase 2 | |
Terminated |
NCT03864328 -
A Phase 2b Study of Inhaled RVT-1601 for the Treatment of Persistent Cough in IPF
|
Phase 2 | |
Completed |
NCT05803850 -
A Study to Evaluate the Safety, Tolerability, PK and PD of HNC1058
|
Phase 1 | |
Withdrawn |
NCT05349760 -
A Phase 2 Study to Evaluate Safety and Efficacy of AMB-05X in Subjects With Idiopathic Pulmonary Fibrosis
|
Phase 2 | |
Completed |
NCT01266317 -
Combined PEX, Rituximab and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations
|
Phase 1/Phase 2 | |
Recruiting |
NCT05147597 -
Turkish Validity and Reliability of SGRQ-I
|
||
Completed |
NCT04503044 -
ILAs in CT Lung Cancer Screening Population
|
||
Recruiting |
NCT04564183 -
Advancing Prevention of Pulmonary Fibrosis
|
||
Recruiting |
NCT05190211 -
Telerehabilitation in Patients With Idiopathic Pulmonary Fibrosis
|
N/A | |
Recruiting |
NCT04263727 -
A Study of Patients With Chronic Disease
|
||
Completed |
NCT05353556 -
Effects of Home-based Inspiratory Muscle Training in Patients With IPF
|
N/A | |
Completed |
NCT02976935 -
Functional MR Lung Imaging Using Hyperpolarised 129Xe
|
||
Recruiting |
NCT05193136 -
Sleep Hygiene, Sarcopenia, and Cognitive Function in Respiratory Disease
|
||
Recruiting |
NCT06181370 -
Phase I Study to Assess Safety, Tolerability, PK and PD of AGMB-447 in Healthy Participants and Participants With IPF
|
Phase 1 | |
Not yet recruiting |
NCT02885961 -
The Coagulation Cascade in Idiopathic Pulmonary Fibrosis
|
N/A |